CRISPR / Cas14 nucleic acid detection method of rifampicin drug-resistant mycobacterium tuberculosis

The CRISPR/Cas14 system identified single-base mutations in the rpoB gene of Mycobacterium tuberculosis, which solved the problems of long detection time, high cost and high missed detection rate in the prior art, and achieved drug-resistant Mycobacterium tuberculosis in rifampin The rapid and accurate detection of the patient has important clinical diagnosis and guidance significance.

CN119040487APending Publication Date: 2024-11-29ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311096155.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-08-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art has problems such as long detection time, high cost and high missed detection rate in detecting Mycobacterium tuberculosis and its drug resistance, especially the rapid and accurate detection of Mycobacterium tuberculosis resistant to rifampin is difficult to achieve.

Method used

The CRISPR/Cas14 system was used to identify single-base mutations at positions 531 and 526 of the rpoB gene of Mycobacterium tuberculosis through Cas14 protein and specific crRNA or sgRNA. It was used to quickly detect the CRISPR/Cas14 system and reagents were constructed. box, achieves fast and accurate drug resistance detection.

Benefits of technology

It has achieved rapid and accurate detection of rifampicin-resistant Mycobacterium tuberculosis, reduced the detection cost and time, improved the sensitivity and specificity of the detection, and has important clinical diagnosis and drug guidance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004419177650000061
    Figure BDA0004419177650000061
  • Figure BDA0004419177650000091
    Figure BDA0004419177650000091
  • Figure HDA0004419177660000011
    Figure HDA0004419177660000011
Patent Text Reader

Abstract

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas14 (clustered regularly interspaced short palindromic repeats) nucleic acid detection method for The invention provides a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas14 (CRISPR / Cas14) system for detecting rifampicin drug-resistant mycobacterium tuberculosis, which comprises Cas14 protein, crRNA (crRNA) and tracRNA (or sgRNA, namely single-chain RNA formed by fusing the crRNA and the tracRNA), or a complex formed by the Cas14 protein, the crRNA and the tracRNA, the crRNA comprises a guide sequence of a target spot sequence of targeted rifampicin drug-resistant mycobacterium tuberculosis; the target sequence of the rifampicin drug-resistant mycobacterium tuberculosis is as shown in SEQ ID No. 1 and / or SEQ ID No. 2. The CRISPR / Cas14 system provided by the invention can be used for specifically detecting the rifampicin drug-resistant mycobacterium tuberculosis. The invention has important significance for timely and rapidly detecting whether the mycobacterium tuberculosis has rifampicin drug resistance related site mutation or not.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a CRISPR / Cas14 nucleic acid detection method for rifampicin-resistant Mycobacterium tuberculosis. Background Art

[0002] Tuberculosis is a disease caused by Mycobacterium tuberculosis (MTB) that seriously threatens human health. According to the 2021 WHO tuberculosis report, a quarter of the world's population, about 2 billion people, are infected with Mycobacterium tuberculosis. The early symptoms of tuberculosis are not obvious and difficult to detect. If not treated with drugs, the mortality rate can be as high as 70% within ten years. The treatment of drug-resistant MTB is more difficult and expensive, which poses a huge challenge to the prevention and treatment of tuberculosis. Because MTB grows slowly, traditional detection methods take a long time to detect and analyze its drug resistance, and have a high rate of missed detection, which may cause patients to miss the best time for treatment. Therefore, rapid and accurate detection of MTB and drug-resistant MTB is of great significance for the prevention and treatment of tuberculosis.

[0003] At present, traditional MTB detection methods, such as microscopy and culture, are complex and time-consuming. New molecular diagnostic methods, such as GeneXpert, are widely used in clinical practice and have fast detection speeds. However, their disadvantages are that they are expensive and require expensive equipment. Rifampicin (RIF) is the first-line drug for the treatment of tuberculosis. About 95% of RIF-resistant MTB are caused by mutations in the rpoB gene encoding the RNA polymerase β subunit [Zhang Lingfeng and Gao Mei, Analysis of rpoβ mutations in rifampicin-related genes of multidrug-resistant Mycobacterium tuberculosis. Contemporary Medicine, 2013.19(20):p.15-16.]. The vast majority of rpoB resistance-related mutations occur in the rifampicin resistance-determining region (RRDR), with the most common mutations occurring at codons 516, 526, and 531. About 90% of MTB are resistant to both RIF and INH. Therefore, RIF resistance is considered an important marker of multidrug resistance. Detection of RIF resistance has important guiding significance for the rational use of drugs in the clinical treatment of tuberculosis. Summary of the invention

[0004] The purpose of the present invention is to provide a CRISPR / Cas14 nucleic acid detection method for rifampicin-resistant Mycobacterium tuberculosis, and a corresponding CRISPR / Cas14 system.

[0005] In a first aspect, the present invention claims a complete CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis.

[0006] The complete CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis claimed in the present invention consists of CRISPR / Cas14 system 1 and CRISPR / Cas14 system 2.

[0007] The CRISPR / Cas14 system 1 is used to detect a single base mutation at position 531 of the rpoB gene of Mycobacterium tuberculosis, and the CRISPR / Cas14 system 2 is used to detect a single base mutation at position 526 of the rpoB gene of Mycobacterium tuberculosis.

[0008] The CRISPR / Cas14 system 1 comprises the following (A1) or (A2):

[0009] (A1) Cas14 protein, crRNA1 and tracRNA, or a complex formed by the three; the crRNA1 includes a guide sequence 1 targeting a target sequence 1; the target sequence 1 (including position 531 of the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis) is as shown in SEQ ID No. 1;

[0010] (A2) Cas14 protein, sgRNA1, or a complex formed by the two; the sgRNA1 is a single-stranded RNA formed by the fusion of the crRNA1 and the tracRNA;

[0011] The CRISPR / Cas14 system 2 comprises the following (B1) or (B2):

[0012] (B1) Cas14 protein, crRNA2 and tracRNA, or a complex formed by the three; the crRNA2 includes a guide sequence 2 targeting a target sequence 2; the target sequence 2 (including position 526 of the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis) is shown in SEQ ID No. 2;

[0013] (B2) Cas14 protein, sgRNA2, or a complex formed by the two; the sgRNA2 is a single-stranded RNA formed by the fusion of the crRNA2 and the tracRNA.

[0014] Furthermore, the guide sequence 1 is shown as positions 206-255 of SEQ ID No.3.

[0015] Furthermore, the guide sequence 2 is shown as positions 206-255 of SEQ ID No.4.

[0016] In a specific embodiment of the present invention, the sequence of the sgRNA1 is shown as SEQ ID No.3.

[0017] In a specific embodiment of the present invention, the sequence of the sgRNA2 is shown as SEQ ID No.4.

[0018] In a specific embodiment of the present invention, the Cas14 protein is Cas14a.

[0019] In a second aspect, the present invention claims a CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis.

[0020] The CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis claimed in the present invention may be the CRISPR / Cas14 system 1 or the CRISPR / Cas14 system 2 described in the first aspect above.

[0021] In a third aspect, the present invention claims a kit for detecting rifampicin-resistant Mycobacterium tuberculosis.

[0022] The kit for detecting rifampicin-resistant Mycobacterium tuberculosis claimed in the present invention may be any of the following:

[0023] (C1) Kit 1, comprising the CRISPR / Cas14 system 1 described in the first aspect above;

[0024] (C2) Kit 2, comprising the CRISPR / Cas14 system 2 described in the first aspect above;

[0025] (C3) Kit 3, comprising the complete CRISPR / Cas14 system described in the first aspect above.

[0026] Furthermore, the kit may also include a primer pair for specifically amplifying the resistance-determining region of the rpoB gene of rifampicin-resistant Mycobacterium; the primer pair consists of two single-stranded DNAs shown in SEQ ID No.5 and SEQ ID No.6.

[0027] Furthermore, the kit may also include a fluorescent reporter molecule; the fluorescent reporter molecule is a single-stranded DNA shown in SEQ ID No. 7, and has a FAM fluorescent group and a BHQ1 quenching group at both ends respectively.

[0028] In a fourth aspect, the present invention claims protection for any of the following substances:

[0029] (D1) crRNA1 and / or crRNA2 described in the first aspect above;

[0030] (D2) the sgRNA1 and / or the sgRNA2 described in the first aspect above;

[0031] (D3) Primer pair 1 and / or primer pair 2 described in the first aspect above.

[0032] In a fifth aspect, the present invention claims a method for detecting rifampicin-resistant Mycobacterium tuberculosis.

[0033] The method for detecting rifampicin-resistant Mycobacterium tuberculosis claimed in the present invention may be the following method I, method II or method III:

[0034] Method I: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 531 of the rpoB gene, which may include the following steps (E1)-(E3):

[0035] (E1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in the third aspect above to obtain a single-stranded DNA fragment of the target nucleic acid;

[0036] (E2) preparing a CRISPR-Cas14 detection system 1 comprising the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in the first aspect above, the crRNA1 and tracRNA described in the first aspect above or the sgRNA1 described in the first aspect above, and the fluorescent reporter molecule described in the third aspect above;

[0037] (E3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system 1, and determining whether the sample to be tested contains or is a candidate for containing rifampicin-resistant Mycobacterium tuberculosis due to a single base mutation at 531 of the rpoB gene according to the fluorescence intensity.

[0038] The result determination method can be as follows: when the fluorescence value at 30 minutes of detection is greater than the sum of the mean value of the negative sample signal and 3 times the standard deviation, it is determined to be positive.

[0039] Method II: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 526 of the rpoB gene, which may include the following steps (F1)-(F3):

[0040] (F1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in the third aspect above to obtain a single-stranded DNA fragment of the target nucleic acid;

[0041] (F2) preparing a CRISPR-Cas14 detection system 2 containing the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in the first aspect above, the crRNA2 and tracRNA described in the first aspect above or the sgRNA2 described in the first aspect above, and the fluorescent reporter molecule described in the third aspect above;

[0042] (F3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system 2, and determining whether the sample to be tested contains or is a candidate for containing rifampicin-resistant Mycobacterium tuberculosis due to a single base mutation at 526 of the rpoB gene according to the fluorescence intensity.

[0043] The result determination method can be as follows: when the fluorescence value at 30 minutes of detection is greater than the sum of the mean value of the negative sample signal and 3 times the standard deviation, it is determined to be positive.

[0044] Method III: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by single base mutations at positions 531 and / or 526 of the rpoB gene, comprising the following steps (G1)-(G3):

[0045] (G1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in the third aspect above to obtain a single-stranded DNA fragment of the target nucleic acid;

[0046] (G2) preparing a CRISPR-Cas14 detection system 3 containing the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in the first aspect above, the crRNA1, the crRNA2 and the tracRNA described in the first aspect above or the sgRNA1 and the sgRNA2 described in the first aspect above, and the fluorescent reporter molecule described in the third aspect above;

[0047] (G3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system 3, and determining whether the sample to be tested contains or is a candidate for containing rifampicin-resistant Mycobacterium tuberculosis due to single base mutations at positions 531 and / or 526 of the rpoB gene based on the fluorescence intensity.

[0048] The result determination method can be as follows: when the fluorescence value at 30 minutes of detection is greater than the sum of the mean value of the negative sample signal and 3 times the standard deviation, it is determined to be positive.

[0049] Furthermore, in steps (E1), (F1) and (G1), when the asymmetric PCR is performed, the molar concentration of the primer shown in SEQ ID No. 6 is 10 times that of the primer shown in SEQ ID No. 5.

[0050] Furthermore, in steps (E2), (F2) and (G2), the CRISPR-Cas14 detection system also contains 10×CutSmart.

[0051] Further, in steps (E3), (F3) and (G3), the fluorescence intensity of the CRISPR-Cas14 detection system is detected by selecting an excitation wavelength of 490 nm and an emission wavelength of 520 nm, setting the detection temperature to 45°C, reading the plate once every 1 min, and the total time is 2 h.

[0052] The sample to be tested may be Mycobacterium tuberculosis. Furthermore, it may be either rifampicin-resistant Mycobacterium tuberculosis or rifampicin-inresistant Mycobacterium tuberculosis.

[0053] The method for detecting rifampicin-resistant Mycobacterium tuberculosis provided by the present invention can be a non-disease diagnosis and treatment method or a disease diagnosis and treatment method. The non-disease diagnosis and treatment method can be, for example, to detect whether and how much rifampicin-resistant Mycobacterium tuberculosis is contained in cells before and after drug administration when screening for rifampicin-resistant Mycobacterium tuberculosis sensitive drugs at the cell level.

[0054] In a sixth aspect, the present invention claims protection for any of the following applications:

[0055] (H1) Use of the complete CRISPR / Cas14 system described in the first aspect above, or the CRISPR / Cas14 system described in the second aspect above, or the kit described in the third aspect above, or the substance described in the fourth aspect above in detecting rifampicin-resistant Mycobacterium tuberculosis or in preparing a product for detecting rifampicin-resistant Mycobacterium tuberculosis.

[0056] (H2) Use of the complete set of CRISPR / Cas14 system described in the first aspect above, or the CRISPR / Cas14 system described in the second aspect above, or the kit described in the third aspect above, or the substance described in the fourth aspect above, or the method described in the fifth aspect above in screening for drugs sensitive to rifampicin-resistant Mycobacterium tuberculosis or in preparing products for screening for drugs sensitive to rifampicin-resistant Mycobacterium tuberculosis.

[0057] (H3) Use of the complete set of CRISPR / Cas14 system described in the first aspect above, or the CRISPR / Cas14 system described in the second aspect above, or the kit described in the third aspect above, or the substance described in the fourth aspect above, or the method described in the fifth aspect above in evaluating the efficacy of a drug against rifampicin-resistant Mycobacterium tuberculosis or in preparing a product for evaluating the efficacy of a drug against rifampicin-resistant Mycobacterium tuberculosis.

[0058] In the above aspects, the rifampicin-resistant Mycobacterium tuberculosis may specifically be Mycobacterium tuberculosis with rifampicin resistance caused by single base mutations at positions 531 and / or 526 of the rpoB gene.

[0059] The present invention utilizes the characteristics of Cas14a protein recognition of target sequence, which is independent of the protospacer adjacent motif (PAM) and has strong recognition ability for single nucleotide mutations, to construct a nucleic acid detection system capable of detecting rifampicin-resistant Mycobacterium tuberculosis. The results show that the system can specifically detect rifampicin-resistant Mycobacterium tuberculosis. The present invention is of great significance for the timely and rapid detection of Mycobacterium tuberculosis and whether there are mutations in rifampicin-resistant related sites, and for the epidemic analysis, clinical diagnosis and medication guidance of drug-resistant tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 This is the result of colony PCR identification after inserting the crRNA gene fragment (guide sequence) corresponding to the 531-position target sequence and the 526-position target sequence into the pSMART plasmid.

[0061] Figure 2 The Cas14 detection system detects single base mutations at positions 531 or 526 of the rpoB gene. The left picture shows the results of the mutation detection at position 531 (513-T is a mutant, 513-C is a wild type), and the right picture shows the results of the mutation detection at position 526 (526-G ​​is a mutant, 526-C is a wild type).

[0062] Figure 3 Results of double-site mutation substrate detection by 531-TL and 526-EL sgRNA. (a) is the real-time fluorescence detection result; (b) is the fluorescence value bar graph at 70 minutes of detection.

[0063] Figure 4 These are the sensitivity experimental results of the Cas14 detection system for detecting the 531 mutation in the rpoB gene. DETAILED DESCRIPTION

[0064] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0065] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0066] Example 1. Establishment and application of CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis

[0067] 1. Experimental Materials

[0068] pLBH531_MBP-Cas14a1 expression plasmid was purchased from Addgene (ID: 112500); DH5α competent E. coli was purchased from Beijing Qingke Biotechnology Co., Ltd., and oligonucleotide forward and reverse strands and PCR amplification primers were synthesized by Beijing Qingke Biotechnology Co., Ltd. pSMART plasmid was purchased from Tianyi Huiyuan Biotechnology Co., Ltd.; TranscriptAid T7 HighYield Transcription Kit was purchased from Thermo Scientific; TEV enzyme, BbsI endonuclease, T4 ligase, and 10× Cutsmart buffer were purchased from NEB, USA; PCR MIX was purchased from Beijing Qingke Biotechnology Co., Ltd.; QIAquickRCR Purification Kit and QIAprep Spin Miniprep Kit were purchased from Qiagen, Germany. The main instruments include PCR instrument (T100TM Thermal Cycler, BIO-RAD), SpectraMax M2 (Molecular Devices), full temperature shaking incubator (Shanghai Peiying Experimental Instrument Co., Ltd.), constant temperature incubator (Tianjin Test Instrument Co., Ltd.), NanoDrop2000 (Thermo Fisher). Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize fluorescent reporter molecules, which are single-stranded DNA composed of 12 T bases, with FAM fluorescent groups and BHQ1 quenching groups modified at both ends.

[0069] 2. Experimental Methods

[0070] 1. Acquisition of Cas14a protein

[0071] The pLBH531_MBP-Cas14a1 expression plasmid was transformed into BL21(DE3) competent cells by chemical transformation. Monoclonal colonies with good protein expression were selected and inoculated into liquid LB medium containing ampicillin antibiotics. Cultured at 37℃200rpm until OD 600=0.8, add IPTG to a final concentration of 0.5mM, and induce expression for 16h. After induction, collect the bacteria by centrifugation. Wash the bacteria twice with an appropriate volume of PBS. Resuspend the bacteria with Lysis Buffer, add protease inhibitors and ultrasonically lyse in an ice bath for 30min, centrifuge for 15min, and collect the supernatant. Filter with a 0.22μm filter, add to a nickel column equilibrated with Lysis Buffer, and incubate at 4℃ for 1h. Then wash the nickel column with Wash buffer I, Wash buffer II, and Wash buffer III respectively. For the components of various buffers, see the instructions of the nickel column affinity chromatography kit. Finally, elute the target protein with Elution buffer, collect 0.5ml in each tube, and measure OD 280 , and combine the proteins with a concentration greater than 1.0 mg / mL. Prepare the enzyme digestion system according to Table 1. After overnight digestion at 4°C, hang the nickel column to remove the MBP-tagged protein. Collect the protein after hanging the column and measure the protein concentration using the BCA protein detection kit. Aliquot the protein and freeze it at -80°C.

[0072] Table 1. TEV enzyme digestion system

[0073]

[0074] 2. sgRNA transcription template design

[0075] The rpoB gene sequence of the standard strain of Mycobacterium tuberculosis H37Rv was downloaded from the NCBI database. According to the literature [Cao Yiming, et al., Characteristics of base mutations at positions 531, 526, and 516 of the rpoB gene of rifampicin-resistant strains of Mycobacterium tuberculosis in China. Modern Hospital, 2015.15(07):p.7-9+12.], the 531 codon C→T mutation was selected to design a 20 bp target sequence 1, as follows:

[0076] 5'-GCCCCAGCGCCAACAGTCGG-3' (SEQ ID No. 1).

[0077] According to the 526th codon C→G, a 20bp target sequence 2 was designed as follows:

[0078] 5'-CGGCGCTTGTCGGTCAACCC-3' (SEQ ID No. 2).

[0079] The corresponding complementary oligonucleotide sequences were designed accordingly, see Table 2.

[0080] Table 2. Complementary oligonucleotide sequences corresponding to the target sequences at sites 531 and 526

[0081] name Sequence (5'-3') 531-TLOligo-F CAACCCGACTGTTGGCGCTGGGGC 531-TLOligo-R AAACGCCCCAGCGCCAACAGTCGG 526-ELOligo-F CAACGGGTTGACCGACAAGCGCCG 526-EL Oligo-R AAACCGGCGCTTGTCGGTCAACCC

[0082] 3. Construction of plasmid corresponding to sgRNA transcription template

[0083] The T7 promoter and the coding DNA sequence of tracRNA were directly connected head to tail and inserted between the two restriction sites of BamHI and EcoRI on the pSMART vector. Among them, the T7 promoter sequence: TAATACGACTCACTATAGGG (20bp), the tracrRNA sequence: CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAA AGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUU CUUCGGAAAGUAACCCUCGAAACAAAUUCAUUUUUUCCUCUCCAAUUCUGCACAAGAAAGUUGCAGAACCCGAA UAGACGAAUGAAGGAAUGCAAC (202bp). Then, two BbSI restriction sites were inserted after the tracrRNA sequence, and the modified plasmid was obtained after sequencing verification, which was named pSMART-1. Synthesize two complementary oligonucleotide chains corresponding to the target sequences at sites 531 and 526, respectively, and the sequences are shown in Table 2. Prepare the annealing system according to Table 3, 95℃5min, anneal at 56℃15min. Add the annealed double-stranded DNA to the connection system according to Table 4 and place it on the PCR instrument for reaction. The reaction conditions are 37℃5min, 25℃5min, 10 cycles: then 37℃30min, 65℃5min.

[0084] Table 3. Oligonucleotide annealing system

[0085] Components Dosage 100μM ligo-F 9μL 100μM ligo-R 9μL 10×TE buffer 2μL Total volume 20μl

[0086] Table 4. Ligation reaction system

[0087] Components Dosage 10×T4 Ligation Buffer 2μL Annealing product 1μL pSMART-1 Plasmid 100ng BbsI endonuclease 1μL T4 Ligase 1μL Enzyme-free water Make up to 20 μL Total volume 20μL

[0088] 4. Obtaining plasmids corresponding to 531-TLsgRNA and 526-ELsgRNA transcription templates

[0089] Add the ligation product obtained in step 3 to the DH5α competent cells in the ice bath and mix thoroughly. After ice bathing for 30 minutes, heat shock at 42°C for 90 seconds and let stand on ice for 5 minutes. Add 800μL liquid LB medium and incubate at 200rpm at 37°C for 1 hour. Take an appropriate amount of bacterial solution and spread it on the kanamycin-resistant LB plate, invert it in a 37°C constant temperature incubator and culture it overnight. Pick the monoclonal colonies grown on the solid plate and streak them. After the colonies grow, pick some colonies with a gun tip and resuspend them in 50μL ultrapure water. After heating at 99°C for 10 minutes, centrifuge at 1200rpm for 3 minutes and take 3μL of supernatant as a template for colony PCR identification.

[0090] The upstream and downstream primer sequences for plasmid colony PCR amplification corresponding to the 531-TL sgRNA transcription template are:

[0091] 531F: 5'-CCCCCCGTTCAGCCCGACCG-3';

[0092] 531-RTL: 5'-GCCCCAGCGCCAACAGTCGGGTTG-3'.

[0093] The upstream primer for PCR identification of plasmid colonies corresponding to the 526-ELsgRNA transcription template is 531F, and the downstream primer is:

[0094] 526-REL: 5'-CGGCGCTTGTCGGTCAACCCGTTG-3'.

[0095] The colony PCR amplification system is shown in Table 5. The amplification conditions are 98°C for 2 min; 98°C for 10 s, annealing at 62°C for 10 s, extension at 72°C for 10 s, 35 cycles; 72°C for 5 min.

[0096] Table 5. PCR amplification system for positive colony identification

[0097] Components Dosage template 3μL 10 μM upstream and downstream primers 2μL each PCR MIX 43μL Total volume 50μL

[0098] After amplification, 10 μL was taken for agarose gel electrophoresis, and the monoclonal colonies that amplified the target band were selected for sequencing, and the colonies with correct sequencing results were selected for subsequent experiments.

[0099] 5. sgRNA transcription and purification

[0100] Take 100 μL of the preserved bacterial solution and inoculate it into 5 mL of kanamycin-resistant liquid LB medium to culture until OD600 = 1.0, collect the bacteria by centrifugation, and extract the plasmid using a plasmid extraction kit. Use the purified plasmid as a template and use primers 531F / 531-RTL and 526F / 526-REL (see above for specific sequences) for PCR amplification. The amplification system and conditions are the same as those for colony identification PCR in step 3.

[0101] The amplified product was purified using a PCR product kit, and the purified PCR product was used as a template for in vitro transcription according to Table 6, and the reaction was carried out at 37° C. for 2 h.

[0102] Table 6. Transcription system

[0103] Components Dosage DNA template 1 μg 5×TranscriptAid Reaction Buffer 4μL ATP / CTP / GTP / UTP mix 8μL TranscriptAid Enzyme Mix 2μL DEPC-treated water Make up to 20 μL Total volume 20μL

[0104] The transcription product was purified using an RNA purification kit and electrophoresed in a 1% agarose gel for 30 min. The concentration of the obtained sgRNA was detected using NanoDrop2000.

[0105] 6. Synthesis of detection targets

[0106] The wild-type ssDNA substrate sequence is named WT, with a length of 150 bp, and contains the entire RRDR region of the rpoB gene. The 531 and 526 site mutation substrates are named 531M and 526M, respectively, which are completely identical to WT except for one base difference in the codon at position 531 or 526. The substrates were synthesized by Qingke Biotechnology Co., Ltd., and the sequence is shown in Table 7 (the mutation site is underlined).

[0107] Table 7. WT, 531M and 526M substrate sequences

[0108]

[0109] 7. Detection of target amplification

[0110] Primers were designed for the RRDR region as follows:

[0111] RRDR-2F: 5'-TCCGGCCGGTGGTCGCCGCGATCAAG-3' (SEQ ID No. 5);

[0112] RRDR-2R: 5'-GATCGGGCACATCCGGCCGTAGTGCG-3' (SEQ ID No. 6).

[0113] The whole genome DNA of the sample to be tested (such as Mycobacterium tuberculosis) is used as a template, and the primers are used for asymmetric PCR amplification. The composition of the amplification system is shown in Table 8. The amplification conditions are 98℃ for 2min; 98℃ for 10s, annealing at 58℃ for 10s, extension at 72℃ for 10s, 50 cycles; 72℃ for 2min. The product is single-stranded DNA.

[0114] Table 8. Asymmetric PCR amplification system

[0115] Components Dosage template 3μL 1 μM upstream primer 1μL 10 μM downstream primer 1μL PCR MIX 45μL Total volume 50μL

[0116] 8. Detection of drug resistance-related point mutations in the rpoB gene of Mycobacterium tuberculosis by the Cas14 detection system

[0117] The composition of the Cas14 nucleic acid detection system is shown in Table 9. After adding the various components required for the detection system to the 96-well all-black detection plate in turn, put it into the SpectraMax M2 enzyme label detector, select 490nm excitation wavelength and 520nm emission wavelength, set the detection temperature to 45°C, read the plate once every 1min, and the total time is 2h.

[0118] Table 9. Cas14 detection system

[0119] Components Dosage Cas14a 500nM sgRNA 250nM 10 × CutSmart 5μL Fluorescent reporter molecules 1μM Asymmetric PCR products 100nM water Make up to 50 μL Total volume 50μL

[0120] Wherein, the fluorescent probe is specifically as follows:

[0121] 5'FAM-TTTTTTTTTTTT-3'BHQ1 (SEQ ID No. 7).

[0122] Result determination: When the fluorescence value at 30 minutes of detection is greater than the sum of the signal mean and 3 times the standard deviation of the negative sample (the sample control without target nucleic acid in the detection system), it is determined to be positive.

[0123] 9. Evaluation of the sensitivity of Cas14 detection system for detecting C→T mutation at site 531 of rpoB gene of Mycobacterium tuberculosis

[0124] The whole genome of rifampin-resistant Mycobacterium tuberculosis with a mutation at codon 531 confirmed by rpoB gene sequencing (described in “Yong Zhao, et al. Locked Nucleic Acid Probe-Based Real-Time PCR Assay for the Rapid Detection of Rifampin-Resistant Mycobacterium tuberculosis. PLOS ONE | DOI: 10.1371 / journal.pone.0143444 November 24, 2015”, which is available to the public from the applicant and can only be used to repeat the experiment of the present invention and cannot be used for other purposes) was used as a template and gradiently diluted to 1, 10 -1 ,10 -2 ,10 -3 ,10 -4 ,10 -5 , 10 -6 ng / μL, and asymmetric PCR amplification was performed using the diluted DNA as a template according to Table 8. The amplified product was added to the detection system for detection according to Table 9 to perform sensitivity testing.

[0125] 3. Results and Analysis

[0126] 1. Obtaining 531-TL sgRNA and 526-EL sgRNA

[0127] The double-stranded clones formed by annealing 531-TL Oligo-F / R and 526-EL Oligo-F / R (Table 2) were cloned into the pSMART-1 vector. After the colonies grew, the primer pairs 531F / 531-TLR and 531F / 526-ELR (sequences are shown in step 2 above) were used for colony PCR identification. The results showed that the single clones with the amplified fragment size consistent with the theoretical length of 706 bp were selected for both the 531 and 526 target sequences, see Figure 1 Two positively identified monoclonal colonies were selected to extract plasmids for sequencing. The sequencing results showed that the crRNA target gene fragment (guide sequence) for binding to the target sequence shown in SEQ ID No. 1 or SEQ ID No. 2 had been inserted into the pSMART-1 plasmid without point mutation. The obtained recombinant plasmids were named pSMART-531-sgRNA and pSMART-526-sgRNA, respectively.

[0128] The structure of the recombinant plasmid pSMART-531-sgRNA is described as follows: a recombinant plasmid obtained by cloning the double-stranded strand formed by annealing 531-TL Oligo-F / R into two Bbs I sites of the pSMART-1 vector.

[0129] The structure of the recombinant plasmid pSMART-526-sgRNA is described as follows: the recombinant plasmid obtained by cloning 526-EL Oligo-F / R between two Bbs I sites of the pSMART-1 vector.

[0130] 2. sgRNA transcription

[0131] The extracted pSMART-531-sgRNA and pSMART-526-sgRNA plasmids were used as templates, and PCR amplification was performed with primer pairs 531F / 531-TLR and 531F / 526-ELR (sequences are shown in step 2 4 above). The expected amplified product length was 706 bp, and a bright band was visible between 500-750 bp after agarose gel electrophoresis. After the size was in line with expectations, the PCR product was purified. The purified product was used as a template for transcription according to Table 5 to obtain 531-TLsgRNA and 526-ELsgRNA.

[0132] The sequence of the 531-TLsgRNA finally transcribed is shown in SEQ ID No. 3. Among them, positions 206-225 of SEQ ID No. 3 are guide sequences.

[0133] The sequence of the 526-ELsgRNA finally transcribed is shown in SEQ ID No. 4. Among them, positions 206-225 of SEQ ID No. 4 are guide sequences.

[0134] 3. CRISPR / Cas14 detection of single base mutations at position 531 or 526 of the rpoB gene of Mycobacterium tuberculosis

[0135] The synthetic rpoB gene fragment substrates WT, 531M, and 526M were added to the Cas14 detection system for detection, and each sample was repeated three times. The results showed that the Cas14 detection system had a good ability to distinguish the synthetic WT and 531M, 526M single chains. Figure 2 Each data point is the mean of 3 replicates, and the error bars represent the standard deviation.

[0136] 531-TLsgRNA and 526-ELsgRNA were added to the CRISPR / Cas14 detection system at the same time, and the synthetic single-stranded substrates WT, 531M, and 526M containing single 531 site, single 526 site, and 531 / 526 double site mutations were tested. The results are shown in Figure 3 In (a), the fluorescence value at 70 min of detection is plotted as a bar graph. Figure 3 In (b), one-way ANOVA was used for statistical test. The results show:

[0137] The detection system simultaneously added 531-TLsgRNA and 526-ELsgRNA, and the detection of 526M or 531M substrates reached a peak fluorescence value (about 1000RFU) at about 100min, and the detection of 531 / 526 double-site mutation substrates reached a peak value (about 1300RFU) at about 80min, while the detection of WT substrate fluorescence signal remained basically unchanged. This shows that the dual sgRNAs designed in the present invention do not interfere with each other during the detection process, and can detect two mutation sites in one reaction.

[0138] When only 526-ELsgRNA+531M substrate was added to the detection system for detection (orange diamond points) or only 531-TLsgRNA+526M substrate was added for detection (brown squares), there was no fluorescence detection signal, indicating that the present invention has good specificity for detecting point mutations.

[0139] 4. Sensitivity of Cas14 detection system in detecting C→T mutation at site 513 of rpoB gene of Mycobacterium tuberculosis

[0140] The results showed that the nucleic acid concentration was 10 -5 ng / μL, a strong fluorescence signal can be detected, and the detection sensitivity can reach 10 -5 ng / μL, i.e. 3.4aM( Figure 4 ).

[0141] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A complete CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis, comprising CRISPR / Cas14 system 1 and CRISPR / Cas14 system 2; The CRISPR / Cas14 system 1 comprises the following (A1) or (A2): (A1) Cas14 protein, crRNA1 and tracRNA, or a complex formed by the three; the crRNA1 includes a guide sequence 1 targeting a target sequence 1; the target sequence 1 is shown in SEQ ID No. 1; (A2) Cas14 protein, sgRNA1, or a complex formed by the two; the sgRNA1 is a single-stranded RNA formed by the fusion of the crRNA1 and the tracRNA; The CRISPR / Cas14 system 2 comprises the following (B1) or (B2): (B1) Cas14 protein, crRNA2 and tracRNA, or a complex formed by the three; the crRNA2 includes a guide sequence 2 targeting a target sequence 2; the target sequence 2 is shown in SEQ ID No. 2; (B2) Cas14 protein, sgRNA2, or a complex formed by the two; the sgRNA2 is a single-stranded RNA formed by the fusion of the crRNA2 and the tracRNA.

2. The complete CRISPR / Cas14 system according to claim 1, characterized in that: The guide sequence 1 is shown as positions 206-225 of SEQ ID No. 3; and / or The guide sequence 2 is shown as positions 206-225 of SEQ ID No. 4; Furthermore, the sequence of the sgRNA1 is shown in SEQ ID No.3; and / or Furthermore, the sequence of the sgRNA2 is shown in SEQ ID No.

4.

3. The complete CRISPR / Cas14 system according to claim 1 or 2, characterized in that: The Cas14 protein is a Cas14a protein.

4. A CRISPR / Cas14 system for detecting rifampicin-resistant Mycobacterium tuberculosis, which is the CRISPR / Cas14 system 1 or the CRISPR / Cas14 system 2 described in any one of claims 1-3.

5. A kit for detecting rifampicin-resistant Mycobacterium tuberculosis, any of the following: (C1) Kit 1, comprising the CRISPR / Cas14 system 1 described in any one of claims 1 to 3; (C2) Kit 2, comprising the CRISPR / Cas14 system 2 described in any one of claims 1 to 3; (C3) Kit 3, comprising the complete CRISPR / Cas14 system described in any one of claims 1-3.

6. The kit according to claim 4, characterized in that: The kit also includes a primer pair for specifically amplifying the drug resistance determining region of the rpoB gene of rifampicin-resistant mycobacterium; the primer pair consists of two single-stranded DNAs shown in SEQ ID No.5 and SEQ ID No.

6.

7. The kit according to claim 5 or 6, characterized in that: The kit also includes a fluorescent reporter molecule; the fluorescent reporter molecule is a single-stranded DNA shown in SEQ ID No. 7, and has a FAM fluorescent group and a BHQ1 quenching group at both ends.

8. Any of the following substances: (D1) the crRNA1 and / or the crRNA2 described in any one of claims 1 to 3; (D2) the sgRNA1 and / or the sgRNA2 according to any one of claims 1 to 3; (D3) The primer pair 1 and / or the primer pair 2 described in claim 6.

9. A method for detecting rifampicin-resistant Mycobacterium tuberculosis, which is the following method I or method II or method III: Method I: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 531 of the rpoB gene, comprising the following steps (E1)-(E3): (E1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in claim 6 to obtain a single-stranded DNA fragment of the target nucleic acid; (E2) preparing a CRISPR-Cas14 detection system 1 comprising the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in any one of claims 1 to 3, the crRNA1 and tracRNA described in any one of claims 1 to 3 or the sgRNA1 described in any one of claims 1 to 3, and the fluorescent reporter molecule described in claim 7; (E3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system 1, and determining whether the sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 531 of the rpoB gene according to the fluorescence intensity; Method II: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 526 of the rpoB gene, comprising the following steps (F1)-(F3): (F1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in claim 6 to obtain a single-stranded DNA fragment of the target nucleic acid; (F2) preparing a CRISPR-Cas14 detection system 2 containing the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in any one of claims 1 to 3, the crRNA2 and tracRNA described in any one of claims 1 to 3 or the sgRNA2 described in any one of claims 1 to 3, and the fluorescent reporter molecule described in claim 7; (F3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system 2, and determining whether the sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by a single base mutation at 526 of the rpoB gene according to the fluorescence intensity; Method III: A method for detecting whether a sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by single base mutations at positions 531 and / or 526 of the rpoB gene, comprising the following steps (G1)-(G3): (G1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in claim 6 to obtain a single-stranded DNA fragment of the target nucleic acid; (G2) preparing a CRISPR-Cas14 detection system 3 comprising the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in any one of claims 1 to 3, the crRNA1, crRNA2 and tracRNA described in any one of claims 1 to 3 or the sgRNA1 and sgRNA2 described in any one of claims 1 to 3, and the fluorescent reporter molecule described in claim 7; (G3) Detecting the fluorescence intensity of the CRISPR-Cas14 detection system 3, and determining whether the sample to be tested contains rifampicin-resistant Mycobacterium tuberculosis caused by single base mutations at positions 531 and / or 526 of the rpoB gene based on the fluorescence intensity.

10. Any of the following applications: (H1) Use of the complete CRISPR / Cas14 system of any one of claims 1 to 3, or the CRISPR / Cas14 system of claim 4, or the kit of any one of claims 5 to 7, or the substance of claim 8 in detecting rifampicin-resistant Mycobacterium tuberculosis or in preparing a product for detecting rifampicin-resistant Mycobacterium tuberculosis; (H2) Use of the complete set of CRISPR / Cas14 system according to any one of claims 1 to 3, or the CRISPR / Cas14 system according to claim 4, or the kit according to any one of claims 5 to 7, or the substance according to claim 8, or the method according to claim 9 in screening for drug-sensitive Mycobacterium tuberculosis that is rifampicin-resistant or in the preparation of a product for screening for drug-sensitive Mycobacterium tuberculosis that is rifampicin-resistant; (H3) Use of the complete CRISPR / Cas14 system described in any one of claims 1 to 3, or the CRISPR / Cas14 system described in claim 4, or the kit described in any one of claims 5 to 7, or the substance described in claim 8, or the method described in claim 9 in evaluating the efficacy of a drug against rifampicin-resistant Mycobacterium tuberculosis or in preparing a product for evaluating the efficacy of a drug against rifampicin-resistant Mycobacterium tuberculosis.